Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions
Total Income in Q2 FY25 stood at Rs. 532.18 crore
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Growth markets revenue increased by 44 YoY to Rs. 812 crore
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Silica is a proven and highly effective anti-caking agent that has been used for decades
Subscribe To Our Newsletter & Stay Updated
